Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Acquisitions & Divestments (2020 - 2024)

Xeris Biopharma Holdings (XERS) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $10.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Change in Acquisitions & Divestments fell 31.76% year-over-year to $10.2 million, compared with a TTM value of $10.2 million through Sep 2025, down 77.25%, and an annual FY2024 reading of $40.2 million, up 0.59% over the prior year.
  • Change in Acquisitions & Divestments was $10.2 million for Q4 2024 at Xeris Biopharma Holdings, down from $15.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $34.6 million in Q1 2021 and bottomed at $5.0 million in Q1 2024.
  • Average Change in Acquisitions & Divestments over 5 years is $14.8 million, with a median of $11.3 million recorded in 2021.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 80.66% in 2022, then surged 117.86% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $17.8 million in 2020, then tumbled by 41.14% to $10.5 million in 2021, then decreased by 11.43% to $9.3 million in 2022, then surged by 61.29% to $15.0 million in 2023, then tumbled by 31.76% to $10.2 million in 2024.
  • Business Quant data shows Change in Acquisitions & Divestments for XERS at $10.2 million in Q4 2024, $15.0 million in Q3 2024, and $10.0 million in Q2 2024.